Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06097832 · ClinicalTrials.gov registry record · Phase 1
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
A Phase 1 study of Light Chain (AL) Amyloidosis, sponsored by Nexcella.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 18
- Study locations
NCT06097832: Recruiting Phase 1 study of Light Chain (AL) Amyloidosis, sponsored by Nexcella.
NCT06097832 is a Phase 1 study of Light Chain (AL) Amyloidosis that is actively recruiting participants, run by Nexcella. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). The trial reports 18 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06097832, a Phase 1 study of Light Chain (AL) Amyloidosis, is actively recruiting participants, sponsored by Nexcella.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 18
- Study locations
Study Summary
Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).
Primary Outcome
An adverse event (AE) can be any unfavorable and unintended sign (including an abnormal. laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.
Conditions Studied
Interventions
- BIOLOGICAL NXC-201 CAR-T
Study Locations (18)
California
- Sutter Health Alta Bates - Berkeley
- City of Hope - Duarte
- University of California Los Angeles - Los Angeles
- University of California Davis Medical Center - Sacramento
- Stanford University - Stanford
Massachusetts
- Tufts Medical Center - Boston
- Boston University Medical Center - Boston
Ohio
- University of Cincinnati Cancer Center - Cincinnati
- Cleveland Clinic - Cleveland
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Kansas
- The University of Kansas Cancer Center - Fairway
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Missouri
- Washington University Siteman Cancer Center - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-06-05 |
| Est. Completion | 2039-01 |
| Phase | Phase 1 |
What NCT06097832 shows while recruiting
NCT06097832 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Light Chain (AL) Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which NXC-201 CAR-T is the first listed.
NCT06097832 lists 18 locations in 12 states (California, Massachusetts, Ohio).
Frequently Asked Questions
What is clinical trial NCT06097832 about?
NCT06097832 is a clinical study titled "Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis". Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).
What is the current status of trial NCT06097832?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2024-06-05. Estimated completion is 2039-01.
What conditions does trial NCT06097832 study?
This clinical trial studies the following conditions: Light Chain (AL) Amyloidosis.
What interventions are being tested in trial NCT06097832?
The interventions under investigation include: NXC-201 CAR-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT06097832?
This trial is sponsored by Nexcella, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06097832 being conducted?
This trial has 18 study locations across California, Georgia, Kansas, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06097832's enrollment target sits among peer trials
40 1131st of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI